| Ytd | 4.79% | |
| 1y | 4.79% |
| Open | 7.40 | Prev Close | 7.11 | Low | 7.32 | High | 8.45 | Mkt Cap | 405.29M |
| Vol | 5.63M | Avg Vol | 1.26M | EPS | -4.17 | P/E | -1.94 | Forward P/E | N/A |
| Beta | 0.62 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 5.30 | 200-d Avg | 6.02 | 1yr Est | 0.00 |
HELP News
US stocks trade higher as Dow Jones gains over 350 points. Tech shares rise by 2% while consumer sta
US stocks rise, Nasdaq gains 1%. Hasbro Inc (HAS) up 8.6% on strong Q2 results and raised sales guid
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participan
U.S. stocks mixed, Nasdaq falls 150 points. Abbott Labs beats Q2 estimates and raises guidance, sto
JB Hunt Transport Services Inc (JBHT) beat earnings and revenue estimates, causing shares to surge 7
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Helus Pharma (NASDAQ:HELP) with a B
Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ:HELP) with a Buy and low
Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(0.85) per share which beat the analyst con
Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'
- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorde
Health officials explored restricting specific antidepressants among SSRI drugs-sources